Trimethylamine N-Oxide in Heart Failure: A Meta-Analysis of Prognostic Value

Frontiers in Cardiovascular Medicine

article

Xingxing Li¹  Zongjing Fan²  Jie Cui²  Dong Li²  Jinjin Lu²  Xiaoyun Cui²  Liandi Xie²  Yang Wu²  Qian Lin³  Yan Li² 

[1] Second Clinical School of Medicine, Beijing University of Chinese Medicine;Department of Cardiology, Dongfang Hospital, Beijing University of Chinese Medicine;Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine

关键词: heart failure;    trimethylamine N-oxide;    major adverse cardiovascular events;    all-cause mortality;    meta-analysis;   

DOI  :  10.3389/fcvm.2022.817396

学科分类：地球科学(综合)

来源: Frontiers

【 摘 要 】

Objective The present study aimed to explore the prognostic value of trimethylamine N-oxide (TMAO) in heart failure (HF). Methods PubMed, Excerpta Medica Database (EMBASE), Cochrane Library, Web of Science, Wanfang Database, SINOMED, China Science and Technology Journal Database (VIP), and China National Knowledge Infrastructure (CNKI) were searched up to June 1, 2021. Studies recording the major adverse cardiovascular events (MACEs) or all-cause mortality in HF patients and their circulating TMAO concentrations were included. Meta-analysis was performed using Stata 13.0. Results Ten articles (12 studies) involving 13,425 participants from 2014 to 2021 were considered. Compared to low-level TMAO, elevated TMAO was correlated with MACEs and all-cause mortality in HF (RR: 1.28, 95% CI: 1.17, 1.39, P < 0.0001, random-effects model and RR: 1.35, 95% CI: 1.28, 1.42, P < 0.0001, random-effects model, respectively). Consistent results were obtained in all examined subgroups as well as in the sensitivity analysis. Conclusion Elevated TMAO may be an adverse prognostic indicator in patients with HF.

【 授权许可】

CC BY